Kymera Therapeutics (KYMR) Receivables (2020 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Receivables of $40.0 million for Q2 2025, up 1073.71% year-over-year from $3.4 million in Q2 2024, and little changed quarter-over-quarter from $40.0 million in Q1 2025.
Kymera Therapeutics (KYMR) Receivables (2020 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Receivables for 6 consecutive years, with $40.0 million the latest figure, recorded in Q2 2025.
- In Q2 2025, Receivables rose 1073.71% year-over-year to $40.0 million; the TTM figure through Jun 2025 stood at $40.0 million (up 1073.71% YoY), while the FY2024 annual figure was $1.9 million, down 91.61% from the prior year.
- Receivables steadied at $40.0 million in Q2 2025 per KYMR's latest filing, from $40.0 million in the prior quarter.
- Across five years, Receivables topped out at $40.0 million in Q1 2025 and bottomed at $270000.0 in Q4 2021.
- Historically, Receivables has averaged $9.1 million across 5 years, with a median of $4.4 million in 2022.
- Annual changes were most pronounced in 2022 — Receivables jumped 1765.56% — and 2024, when it sank 91.81%.
- Kymera Therapeutics' Receivables stood at $270000.0 in 2021, then surged by 1765.56% to $5.0 million in 2022, then surged by 347.93% to $22.6 million in 2023, then tumbled by 91.81% to $1.8 million in 2024, then surged by 2065.67% to $40.0 million in 2025.
- Business Quant data shows KYMR's Receivables at $40.0 million in Q2 2025, $40.0 million in Q1 2025, and $1.8 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 20.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.00 Mn |
| Jun 30, 2025 | 40.00 Mn |
| Mar 31, 2025 | 40.00 Mn |
| Dec 31, 2024 | 1.85 Mn |
| Sep 30, 2024 | 2.63 Mn |
| Jun 30, 2024 | 3.41 Mn |
| Mar 31, 2024 | 4.06 Mn |
| Dec 31, 2023 | 22.56 Mn |
| Sep 30, 2023 | 7.58 Mn |
| Jun 30, 2023 | 8.24 Mn |
| Mar 31, 2023 | 6.64 Mn |
| Dec 31, 2022 | 5.04 Mn |
| Sep 30, 2022 | 5.78 Mn |
| Jun 30, 2022 | 4.77 Mn |
| Mar 31, 2022 | 2.56 Mn |
| Dec 31, 2021 | 270,000.00 |
| Sep 30, 2021 | 3.17 Mn |
| Jun 30, 2021 | 1.81 Mn |
| Mar 31, 2021 | 2.63 Mn |
| Dec 31, 2020 | 2.01 Mn |